NetScientific plc

Equities

NSCI

GB00BN4R5Q82

Investment Management & Fund Operators

Market Closed - London S.E. 16:35:08 19/06/2024 BST 5-day change 1st Jan Change
73 GBX +1.39% Intraday chart for NetScientific plc +9.77% +21.67%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
NetScientific loss narrows; assets under management top GBP100 million AN
Earnings Flash (NSCI.L) NETSCIENTIFIC Posts FY23 Revenue GBP1.4M MT
Earnings Flash (NSCI.L) NETSCIENTIFIC Reports FY23 Loss GBX-11.20 MT
NetScientific plc Reports Earnings Results for the Full Year Ended December 31, 2023 CI
NetScientific backs Wanda; Inspirit Energy wins deal AN
NetScientific Buys 30% Stake in Wanda Connected Health Systems MT
Wanda Connected Health Systems Limited announced that it has received funding from NetScientific plc CI
Vertu Motors ups dividend as hails record revenue AN
EARNINGS AND TRADING: itim loss narrows; Vela trims EnSilica stake AN
Netscientific Unit Agrees to Manage Martlet Capital’s GBP23 Million Portfolio MT
NetScientific says PDS Biotech's Versamune meets endpoints AN
Netscientific's ProAxsis Secures Investment for Product Development MT
NetScientific investee secures funding to develop product range AN
Empire Metals targets key milestones in Australia AN
NetScientific "significantly" advances strategic goals AN
Esken's Southend Airport faces further allegations AN
Netscientific's Glycotest Receives $1 Million Investment from Fosun MT
Glycotest, Inc. announced that it has received $1 million in funding from EMV Capital Ltd, NetScientific plc, Shanghai Fosun Pharmaceutical Co., Ltd. CI
NetScientific's DeepTech Recycling Closes GBP1 Million Fundraising MT
NetScientific investee DeepTech Recycling bags GBP1 million AN
NetScientific's portfolio company updates on cancer trial AN
Pds Biotech Announces Updated Survival Data from Nci-Led Phase 2 Clinical Trial of Pds0101-Based Triple Combination Therapy in Advanced Hpv16-Positive Cancer Patients CI
NetScientific's EMV Leads Investment Round in Portfolio Company Ventive MT
NetScientific investee claims promising results in biomarker study AN
NetScientific portfolio company updates on cancer trial AN
Chart NetScientific plc
More charts
NetScientific plc is a United Kingdom-based deep tech and life sciences venture capital (VC) investment group with an international portfolio of innovative companies. The Company identifies, invests in, and builds high growth companies in the United Kingdom and internationally. It employs a capital-light investment approach, making use of its balance sheet and syndicating investments through its wholly owned VC subsidiary, EMV Capital Limited. The Company secures a mixture of direct equity stakes and carried interest stakes in its portfolio of companies, creating a structure that can support a large portfolio. Its portfolio consists of a combination of direct investments and capital under advisory (CUA). The Company has about 24 portfolio companies with a focus on life sciences, technology, and sustainability. The Company's subsidiaries include EMV Capital Limited, Glycotest, Inc., and ProAxsis Limited, among others.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.73 GBP
Average target price
1.37 GBP
Spread / Average Target
+87.67%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. NSCI Stock
  4. News NetScientific plc
  5. NetScientific Chairman Moves to Nonexecutive Role, Plans Board Exit in 2023